Rituximab: Beyond simple B cell depletion

Clinical Reviews in Allergy and Immunology

Volumn 34, Issue 1, 2008, Pages 74-79

  Kessel, A ^a   Rosner, I ^a   Toubi, E ^a  

^a BNAI ZION MEDICAL CENTER   (Israel)

Author keywords

B cell depletion; Lymphomas; Rituximab

Indexed keywords

AUTOANTIBODY; B7 ANTIGEN; C REACTIVE PROTEIN; CD20 ANTIBODY; CD40 ANTIGEN; CORTICOSTEROID; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN G; METHOTREXATE; PREDNISOLONE; RHEUMATOID FACTOR; RITUXIMAB;

AUTOIMMUNE DISEASE; B CELL DEPLETION; CELL ACTIVITY; CELL POPULATION; CELL SELECTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; LYMPHOMA; MACROPHAGE; MONOTHERAPY; NATURAL KILLER CELL; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION;

ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOLOGIC FACTORS; KILLER CELLS, NATURAL; LYMPHOCYTE DEPLETION; LYMPHOMA; T-LYMPHOCYTES, REGULATORY;

EID: 49349112380     PISSN: 10800549     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12016-008-8074-1     Document Type: Review

References (29)

1. ME Reff K Carner KS Chambers PC Chinn JE Leonard R Raab 1994 Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 Blood 83 435 445
2. PW Jhonson MJ Glennie 2001 Rituximab: mechanisms and applications Br J Cancer 85 1619 1623
3. AJ Olszewski ML Grossbard 2004 Empowering targeted therapy: lessons from rituximab Sci STKE 241 pe30
4. AJ Grillo-Lopez 2000 Rituximab: an insider's historical perspective Semin Oncol 27 suppl 9 16
5. MJ Shlomchik MP Madaio D Ni M Trounslein D Huszar 1994 The role of B cells in lpr/lpr induced autoimmunity J Exp Med 180 1295 306
6. PE Lipsky 2001 Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity Nat Immunol 2 764 766
7. P Youinou PM Lydyard RA Mageed 2002 B cells underpin lupus immunopathology Lupus 11 1 3
8. A Rivera CC Chen N Ron JP Dougherty Y Ron 2001 Role of B cells as antigen presenting cells in vivo revisited: antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations Int Immunol 13 1583 1593
9. JC Edwards G Cambridge 2001 Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes Rheumatology (Oxford) 40 205 211
10. R Weide J Heymanns A Pandorf H Koppler 2003 Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy Lupus 12 779 782
11. R Ten Cate FJ Smiers RG Bredius AC Lankester LW van Suijlekom-Smit TW Huizinga RM Egeler 2004 Anti-CD20 monoclonal antibody (rituximab) for refractory autoimmune thrombocytopenia in a girl with systemic lupus erythematosus Rheumatology (Oxford) 43 244
12. R Stasi E Stipa G Del Poeta S Amadori AC Newland D Provan 2006 Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab Rheumatology (Oxford) 45 1432 1436
13. JE Gottenberg L Guillevin O Lambotte B Combe Y Allanore A Cantagrel C Larroche 2005 Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases Ann Rheum Dis 64 913 920
14. JC Edwards L Szczepanski J Szechinski A Filipowicz-Sosnowska P Emery DR Close RM Stevens T Shaw 2004 Efficacy of B-cell targeted therapy with rituximab in patients with RA N Eng J Med 350 2572 2581
15. MJ Leandro G Cambridge MR Ehrenstein JC Edwards 2006 Reconstitution of peripheral blood B cells after depletion with rituximab in patients with RA Arthritis Rheum 54 613 620
16. MJ Leandro G Cambridge JC Edwards MR Ehrenstein DA Isenberg 2005 B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients Rheumatology 44 1542 1545
17. PP Sfikakis JN Boletis S Lionaki V Vigklis KG Fragiadaki A Iniotaki HM Moutsopoulos 2005 Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell co-stimulatory molecule CD40 ligand: an open-label trial Arthritis Rheum 52 501 513
18. JH Anolik J Barnard A Cappione AE Pugh-Bernard RE Felgar RJ Looney I Sanz 2004 Rituximab improves peripheral B cell abnormalities in human SLE Arthritis Rheum 50 3580 3590
19. KG Smith RB Jones SM Burns DR Jayne 2006 Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment Arthritis Rheum 54 2970 2982
20. G Cambridge MJ Leandro JC Edwards MR Ehrenstein M Salden M Bodman-Smith AD Webster 2003 Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis Arthritis Rheum 48 2146 2154
21. PP Sfikakis JN Boletis GC Tsokos 2005 Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future Curr Opin Rheumatol 17 550 557
22. A Thatayatikom AJ White 2006 Rituximab: a promising therapy in systemic lupus erythematosus Autoimmunity Rev 5 18 24
23. G Cambridge W Stohl MJ Leandro TS Migone DM Hilbert JC Edwards 2006 Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment Arthritis Rheum 54 723 732
24. E Toubi A Kessel G Slobodin N Boulman E Pavlotzky D Zisman M Rozenbaum I Rosner 2006 Macrophage function changes following rituximab treatment in patients with rheumatoid arthritis Ann Rheum Dis 66 818 820
25. M Tokunaga K Fujii K Saito S Nakayamada S Tsujimura M Nawata Y Tanaka 2005 Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful with rituximab Rheumatology 44 176 182
26. M Vigna-Perez B Hernandez-Castro O Paredes-Sapharopulos D Portales-Perez L Baranda C Abud-Mendoz R Gonzalez-Amaro 2006 Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study Arthritis Res Ther 8 R83
27. T Vallerskog I Gunnarsson M Widhe A Risselada L Klareskog R Van Vollenhoven V Malmstrom C Trollmo 2007 Treatment with rituximab affects both the cellular and the humoral arms of the immune system in patients with SLE Clin Immunol 122 62 74
28. J Golay M Managanini V Facchinetti R gramigna R Broady G Borleri A Rambaldi M Introna 2003 Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by IL-2 Haematologica 88 1002 1012
29. ML Lefebvre SW Krause M Salcedo A Nardin 2006 Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum J Immunother 29 388 397